Clarivate Plc (CLVT) Stock Price & Analysis
Clarivate Plc (CLVT) closed at USD 1.85 on Thursday, October 22, 2026, up 5.11% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 1.76; the Oct 22, 2026 session ranged USD 1.76–1.86 on volume of 3,855,045 shares. Market capitalization is $1.18B, with a 52-week range of USD 1.42–3.87 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 12:51 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CLVT.md
Key facts (CLVT)
- Last four reported quarters (through Jun 30, 2026): revenue $2.41B, net income -$334M (-13.8% margin), free cash flow $328M (SEC filings).
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $4.8M; 1 not under a Rule 10b5-1 plan ($4.8M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 1 Form 4 filing, $1.7M; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Hold (mean 3.00 on a 1–5 scale) (8 analysts), mean target USD 2.97 (range 2–5.5).
- Total return with dividends: 1Y -50.0% vs S&P 500 +14.9%; 5Y -91.7% vs S&P 500 +80.3%.
- Next earnings: 2026-11-03, EPS estimate USD 0.16, revenue estimate $490M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CLVT)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $1.88B | $2.66B | $2.63B | $2.56B | $2.46B | $2.41B |
| Gross profit | $1.25B | $1.71B | $1.72B | $1.69B | $1.62B | — |
| Operating income | -$87.0M | -$3.93B | -$735M | -$276M | $71.5M | -$84.6M |
| Net income | -$271M | -$3.96B | -$911M | -$637M | -$201M | -$334M |
| EPS (diluted) | -$0.61 | -$6.24 | -$1.47 | -$0.96 | -$0.30 | — |
| Free cash flow | $205M | $306M | $502M | $358M | $365M | $328M |
| Gross margin | 66.6% | 64.1% | 65.5% | 66.0% | 66.0% | — |
| Operating margin | -4.6% | -147.6% | -27.9% | -10.8% | 2.9% | -3.5% |
| Net margin | -14.4% | -148.9% | -34.7% | -24.9% | -8.2% | -13.8% |
| Revenue growth | +49.7% | +41.7% | -1.2% | -2.7% | -4.0% | — |
| Cash + short-term investments | $431M | $357M | $371M | $295M | $329M | — |
| Total debt | $5.57B | $5.07B | $4.77B | $4.57B | $4.47B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (CLVT)
P/S 0.5x · EV/EBITDA 7.8x · EV/Sales 2.2x · P/FCF 3.6x · P/B 0.3x · FCF yield 27.68% · Earnings yield -28.22% · Net debt $4.03B · EV $5.22B
Insider sales (SEC Form 4, open-market, last ~7 months) (CLVT)
0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-08-03 | Snyder Andrew Miles | Director | 2,489,618 | $4.8M | 9.5% | No | Too little history (no open-market trades in 2023) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Insider purchases (SEC Form 4, open-market, last ~7 months) (CLVT)
1 purchase, $1.7M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-08-06…2026-08-07 | Cornick Kenneth L. | Director | 900,000 | $1.7M | 1.86 | Too little history (no open-market trades in 2023 or 2024) |
Analysts (CLVT)
Consensus Hold (mean 3.00 on a 1–5 scale), 8 analysts; mean target USD 2.97 (low 2, high 5.5).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-30 | Citigroup | Target lowered | Neutral | $2.8 → $2.5 |
| 2026-07-30 | Goldman Sachs | Target lowered | Neutral | $2.9 → $2.6 |
| 2026-07-30 | Stifel | Target lowered | Buy | $6 → $5 |
| 2026-07-30 | Barclays | Target lowered | Underweight | $2.5 → $2 |
| 2026-07-07 | Barclays | Target raised | Underweight | $2.4 → $2.5 |
Total return (dividends reinvested) (CLVT)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -50.0% | -91.7% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -50.1% | -39.1% |
| Volatility (annualized) | 74.3% | 57.2% |
| Max drawdown | -61.4% (Nov 2025→Oct 2026) | -94.0% (Dec 2021→Sep 2026) |
CLVT revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| A&G | $300.3M | 51.1% | -5.7% |
| IP | $198.3M | 33.8% | -2.1% |
| Life Sciences & Healthcare | $88.7M | 15.1% | -11.7% |
| Total revenue | $587.3M | 100% | — |
CLVT revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Recurring Revenues | $512.6M | 87.3% | -0.4% |
| — Subscription revenues (part of Recurring Revenues) | $403.3M | 68.7% | -0.6% |
| — Re-occurring Revenues (part of Recurring Revenues) | $109.3M | 18.6% | +0.4% |
| Transactional and other revenues | $74.7M | 12.7% | -30.1% |
| Total revenue | $587.3M | 100% | — |
CLVT revenue by region (fiscal year ended Dec 31, 2025)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| North America | $1.30B | 53.1% | -5.7% |
| EMEA | $654.8M | 26.7% | -1.9% |
| Asia Pacific | $497.4M | 20.3% | -2.0% |
| Total revenue | $2.46B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
CLVT analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.16 | $0.17 | -5.6% | $490.1M | 2 |
| Next quarter (ends Dec 2026) | $0.18 | $0.19 | -7.3% | $502.4M | 3 |
| Current fiscal year (ends Dec 2026) | $0.72 | $0.73 | -1.5% | $2.21B | 3 |
| Next fiscal year (ends Dec 2027) | $0.78 | $0.74 | +5.0% | $2.02B | 3 |
CLVT options: expected move
Options price a move of about ±22.7% (±$0.42) by Dec 18, 2026, which includes earnings on Nov 3, 2026. Over the last 8 reports the stock moved ±17.1% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Dec 18, 2026 | 56 | 102.1% | ±22.7% |
| Jan 15, 2027 | 84 | 87.0% | ±31.1% |
| Apr 16, 2027 | 175 | 91.6% | ±51.4% |
30-day implied volatility 85.3% vs 56.1% realized over the last 30 trading days. Put/call ratio (volume) —. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 12:51 UTC)
| Price | USD 1.85 |
|---|---|
| Change | ▲ 5.11% (up) |
| Previous Close | USD 1.76 |
| Open | USD 1.76 |
| Day Range | USD 1.76 – 1.86 |
| 52-Week Range | USD 1.42 – 3.87 |
| Volume | 3,855,045 shares |
| Market Cap | $1.18B |
| Exchange | NYQ |
Technical Analysis (CLVT)
Nexqual's technical model rates CLVT "BUY" based on 4 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 12:51 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 57.24 (neutral) |
| vs SMA50 | Above (USD 1.84) |
| MACD | -0.01 (negative) |
Analyst Ratings (CLVT)
Wall Street analysts rate CLVT "Hold" based on 8 analysts, with a mean price target of USD 2.97 (range USD 2–5.5), per Nexqual as of October 23, 2026 at 12:51 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 2.97 |
| High Target | USD 5.5 |
| Low Target | USD 2 |
| Buy / Hold / Sell | 2 / 5 / 1 |
Earnings (CLVT)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD 0.16 |
| Revenue Estimate | $490.10M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.19 vs est 0.18 ▲ beat |
| 2026-03-31 | USD 0.18 vs est 0.14 ▲ beat |
| 2025-12-31 | USD 0.2 vs est 0.16 ▲ beat |
| 2025-09-30 | USD 0.18 vs est 0.16 ▲ beat |
Source: Nexqual, October 23, 2026 at 12:51 UTC.
Financials & Fundamentals (CLVT)
| Total Revenue | $2.41B |
|---|---|
| Revenue Growth (latest quarter, YoY) | -5.50% |
| Gross Margin | +66.82% |
| Operating Margin | +6.13% |
| Profit Margin | -13.84% |
| ROE | -7.01% |
| Debt / Equity | 0.94 |
| Current Ratio | 0.85 |
| Total Cash | $206.70M |
| Total Debt | $4.26B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $327.60M (13.6% of revenue) |
Source: Nexqual, October 23, 2026 at 12:51 UTC.
Financial Health Score (CLVT)
Nexqual rates Clarivate Plc's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 12:51 UTC.
| Growth | Weak — Revenue -4% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 67%, operating 6% (last 12 months) |
| Balance Sheet | Weak — $218M cash and investments vs $4.25B debt (Jun 2026, SEC) |
| Cash Flow | Solid — FCF $328M (last 4 quarters to Jun 2026, SEC), 14% margin |
| Efficiency | Critical — ROE -7%, ROA 0.9% |
Ownership (CLVT)
| Insider Ownership | +18.33% |
|---|---|
| Institutional Ownership | +93.07% |
| Shares Outstanding | 639.66M |
| Float | 468.64M |
| Short % of Float | +13.66% |
Source: Nexqual, October 23, 2026 at 12:51 UTC.
Leadership (CLVT)
Clarivate Plc is led by Matitiahu Shem Tov, CEO & Director, per Nexqual as of October 23, 2026 at 12:51 UTC.
| CEO & Director | Matitiahu Shem Tov |
|---|---|
| President of Academia & Government | Bar Veinstein |
| Executive VP & CFO | Michael Easton |
| Senior Vice President of Communications & Brand | Gwenan White |
| Senior Vice President of Life Sciences and Healthcare | Richard C. Finch |
Major Backers & Investors (CLVT)
Notable institutional backers of Clarivate Plc include Leonard Green & Partners, L.P., Exor N.V., Clarkston Capital Partners LLC, according to Nexqual as of October 23, 2026 at 12:51 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Leonard Green & Partners, L.P. | 18.24% |
| Exor N.V. | 10.52% |
| Clarkston Capital Partners LLC | 7.15% |
| Partners Group Holding AG | 4% |
| FIL LTD | 3.95% |
| Edmond De Rothschild Holding S.A. | 2.54% |
| ALPS SERIES TRUST-Clarkston Partners Fund | 2.39% |
| Citadel | 2.29% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 4.87% |
| Dimensional Fund Advisors | 2.98% |
Source: Nexqual, October 23, 2026 at 12:51 UTC.
From Clarivate Plc's Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Our AI research assistants enable customers to find, synthesize, and validate trusted insights more efficiently through query-specific, source-backed outputs, while our AI agents automate complex workflows, such as literature reviews, by executing and validating multi-step tasks across our proprietary solutions.
- We work with more than 3,000 customers worldwide across the life sciences and healthcare value chain, including many of the top pharmaceutical, medical device, and biotech companies.
- As a general practice, employees, contractors, and other parties with access to our proprietary information sign agreements that prohibit the unauthorized use or disclosure of our intellectual property and confidential information.
- We have developed and continue to develop AI research assistants and agents to enhance customer adoption and retention, unlock new revenue streams, and extend platform reach.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PONY | Pony AI Inc. | USD 5.02 | ▼ 0.4% |
| CHRN | ChronoScale Holdings Corporatio | USD 15.46 | ▼ 6.98% |
| CSQR | Csquare, Inc. | USD 14.9 | ▼ 11.83% |
| DXC | DXC Technology Company | USD 16.08 | ▲ 4.42% |
| PENG | Penguin Solutions, Inc. | USD 51.91 | ▼ 11.08% |
| KD | Kyndryl Holdings, Inc. | USD 15.2 | ▲ 5.92% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 12:51 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt